LAKE FOREST, Ill., May 20, 2011 /PRNewswire/ -- Hospira, Inc.  (NYSE: HSP ), a leading provider of clinical information and medication delivery technologies, today announced that the company has received regulatory approval from Health Canada for its software upgrade to the Symbiq™ infusion system.  As a result, Hospira has resumed shipments of Symbiq pumps in Canada and is working with current customers in the region to upgrade to the new version of the software.
"With the upgraded Symbiq infusion system, our goal is to provide hospitals with one of the most advanced and highest quality infusion pumps available today," said Gerry Stefanatos, vice president, Canada and Latin America, Hospira. "This regulatory approval is a testament to the work we've done to help ensure the robustness, dependability and flexibility of the Symbiq device. We are now focused on partnering with hospital customers in Canada who are ready to have their current Symbiq system upgraded and new infusion pumps implemented."
The upgraded Symbiq software includes modifications to further ensure the reliability of the device. During the Symbiq modification process, Hospira:
- enhanced the operational performance of the infusion pump to reflect customer feedback and address recent device field corrections,
- improved the device software to perform consistently across varying infusion pump clinical practices, and
- reevaluated the software design to ensure optimal operation within the product specifications.
The Symbiq infusion system is a technologically advanced infusion pump with several clinician-friendly features incorporated to help improve workflow and decrease medication errors. For example, the Symbi